Results

The number of migraine attacks and headache days per month decreased significantly from baseline for both Groups A and B.

Subjects in Group A had considerably more adverse events leading to study withdrawal than in Group B (18% vs 4%).

Though this study was not powered to directly compare the efficacy of the 2 drugs, topiramate showed superiority over frovatriptan at Month 2 in reduction of headache days, which was a secondary end point in the study (P = .036).